Latest News and Press Releases
Want to stay updated on the latest news?
-
- First-in-class checkpoint inhibitor IOS-1002 (targeting LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1) being evaluated as mono and combination therapy in patients with advanced solid tumors Schlieren...
-
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
-
SAN FRANCISCO, March 20, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, leading developer of advanced RNA analysis tools, announced today that they have entered into an agreement with the National...